Soriguer Federico, Valdés Sergio, Tapia María José, Esteva Isabel, Ruiz de Adana María Soledad, Almaraz María Cruz, Morcillo Sonsoles, García Fuentes Eduardo, Rodríguez Francisca, Rojo-Martinez Gemma
Servicio de Endocrinología y Nutrición, Hospital Universitario Carlos Haya, Málaga, España.
Med Clin (Barc). 2012 Apr 14;138(9):371-6. doi: 10.1016/j.medcli.2011.05.025. Epub 2011 Sep 21.
The aim of this study was to validate the ability of the Finnish Diabetes Risk Score (FINDRISC) to predict the risk of DM2 in a population of south-eastern Spain (Pizarra Study).
The Pizarra Study is a population-based prospective study developed in the town of Pizarra (Málaga). The first phase of the study was conducted in 1997-1998, including 1051 individuals aged 18-65 years randomly selected from the municipal census of the town. In 2003-2004 the subjects participating in the first study were reassessed. 824 individuals completed the second phase of the study (78.4%). All participants without known diabetes underwent an oral glucose tolerance test both at baseline and follow-up. We evaluated the ability of the FINDRISC to detect undiagnosed DM2 (first phase: cross-sectional study) and in predicting the incidence of DM2 (second phase: cohort study).
The test showed good results both to detect undiagnosed DM2 (ROC-AUC 0.74) and to predict incident DM2 (ROC-AUC 0.75). The best prediction of risk of incident DM2 was found in those subjects with fasting glucose >100mg/dl and a FINDRISC ≥9 (OR: 19.37; 95%IC: 8,86-42,34; P<.0001).
The results of our study show that FINDRISC can be a useful tool to detect subjects at high risk of diabetes in this population.
本研究旨在验证芬兰糖尿病风险评分（FINDRISC）预测西班牙东南部人群（皮萨拉研究）中2型糖尿病（DM2）风险的能力。
皮萨拉研究是在皮萨拉镇（马拉加）开展的一项基于人群的前瞻性研究。研究的第一阶段于1997 - 1998年进行，包括从该镇市政人口普查中随机选取的1051名年龄在18 - 65岁的个体。2003 - 2004年对参与首次研究的对象进行了重新评估。824名个体完成了研究的第二阶段（78.4%）。所有无已知糖尿病的参与者在基线和随访时均接受了口服葡萄糖耐量试验。我们评估了FINDRISC检测未诊断DM2的能力（第一阶段：横断面研究）以及预测DM2发病率的能力（第二阶段：队列研究）。
该测试在检测未诊断DM2（ROC-AUC 0.74）和预测DM2发病（ROC-AUC 0.75）方面均显示出良好结果。在空腹血糖>100mg/dl且FINDRISC≥9的受试者中发现了对DM2发病风险的最佳预测（OR：19.37；95%IC：8.86 - 42.34；P<0.0001）。
我们的研究结果表明，FINDRISC可作为检测该人群中糖尿病高危个体的有用工具。
